Open AccessIn vitro activity of BMY-28142 in comparison with those of other beta-lactam antimicrobial agents
Author(s) -
Akioyoshi Tsuji,
Antony Maniatis,
Miriam Bertram,
Lowell S. Young
Publication year - 1985
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.27.4.515
Subject(s) - ceftazidime , cefoperazone , cephalosporin , cefotaxime , microbiology and biotechnology , moxalactam , cephem , broth microdilution , antimicrobial , ceftriaxone , minimum inhibitory concentration , agar dilution , klebsiella , enterobacter , serratia , biology , proteus , pseudomonas aeruginosa , imipenem , antibiotics , escherichia coli , pseudomonas , bacteria , antibiotic resistance , biochemistry , carboxylic acid , genetics , gene
The in vitro susceptibility of 406 clinical isolates to BMY-28142, a new semisynthetic cephem, was evaluated and compared with cefpimizole, HR 810, ceftazidime, cefotaxime, moxalactam, and cefoperazone in a broth microdilution assay. On a weight basis, the activity of BMY-28142 against Escherichia coli, Proteus species, and Klebsiella-Enterobacter-Serratia was superior to the other cephems. Against gentamicin-susceptible and -resistant Pseudomonas aeruginosa, BMY-28142 was more active than the other cephems, except ceftazidime and HR 810. A total of 74% of gram-negative and 56% of gram-positive isolates resistant to third-generation cephalosporins were susceptible to less than or equal to 8 micrograms of BMY-28142 per ml. Finally, for 83% of tested isolates, the bactericidal concentration of BMY-28142 was within one dilution of the inhibitory concentration.